Bausch + Lomb (BLCO) Competitors $14.91 +0.28 (+1.91%) As of 09:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLCO vs. SNN, SOLV, PEN, STVN, IRTC, GKOS, TMDX, SLNO, NVST, and LIVNShould you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. Bausch + Lomb vs. Its Competitors Smith & Nephew SNATS Solventum Penumbra Stevanato Group iRhythm Technologies Glaukos TransMedics Group Soleno Therapeutics Envista LivaNova Smith & Nephew SNATS (NYSE:SNN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Do insiders & institutionals have more ownership in SNN or BLCO? 25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 0.2% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, SNN or BLCO? Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Smith & Nephew SNATS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSmith & Nephew SNATS$5.81B2.80$412M$2.1617.18Bausch + Lomb$4.79B1.10-$317M-$0.78-19.04 Is SNN or BLCO more profitable? Smith & Nephew SNATS has a net margin of 0.00% compared to Bausch + Lomb's net margin of -5.58%. Bausch + Lomb's return on equity of 2.33% beat Smith & Nephew SNATS's return on equity.Company Net Margins Return on Equity Return on Assets Smith & Nephew SNATSN/A N/A N/A Bausch + Lomb -5.58%2.33%1.12% Does the media refer more to SNN or BLCO? In the previous week, Smith & Nephew SNATS had 6 more articles in the media than Bausch + Lomb. MarketBeat recorded 8 mentions for Smith & Nephew SNATS and 2 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 1.79 beat Smith & Nephew SNATS's score of 1.34 indicating that Bausch + Lomb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate SNN or BLCO? Smith & Nephew SNATS presently has a consensus price target of $36.00, suggesting a potential downside of 3.01%. Bausch + Lomb has a consensus price target of $15.56, suggesting a potential upside of 4.75%. Given Bausch + Lomb's stronger consensus rating and higher possible upside, analysts plainly believe Bausch + Lomb is more favorable than Smith & Nephew SNATS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew SNATS 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Bausch + Lomb 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.18 Which has more volatility and risk, SNN or BLCO? Smith & Nephew SNATS has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. SummarySmith & Nephew SNATS beats Bausch + Lomb on 10 of the 16 factors compared between the two stocks. Get Bausch + Lomb News Delivered to You Automatically Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLCO vs. The Competition Export to ExcelMetricBausch + LombMedical Services IndustryMedical SectorNYSE ExchangeMarket Cap$5.25B$7.74B$5.77B$21.38BDividend YieldN/A2.66%6.66%3.49%P/E Ratio-19.0179.5683.0529.02Price / Sales1.1047.31527.2348.80Price / Cash7.8124.8225.7018.29Price / Book0.8120.2111.005.30Net Income-$317M$242.04M$3.28B$997.87M7 Day Performance1.81%0.18%-0.19%-0.47%1 Month Performance9.84%5.53%8.33%6.49%1 Year Performance-8.62%10.04%53.31%13.66% Bausch + Lomb Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLCOBausch + Lomb2.2143 of 5 stars$14.85+1.5%$15.56+4.8%-9.8%$5.25B$4.79B-19.0113,500SNNSmith & Nephew SNATS2.7954 of 5 stars$37.20-0.8%$36.00-3.2%+19.6%$16.42B$5.81B17.2217,349News CoveragePositive NewsSOLVSolventum2.2687 of 5 stars$72.82-1.0%$85.75+17.8%+12.0%$12.75B$8.25B13.1622,000Positive NewsAnalyst UpgradePENPenumbra4.8277 of 5 stars$265.19+0.2%$300.47+13.3%+33.3%$10.32B$1.19B70.534,500News CoveragePositive NewsAnalyst ForecastSTVNStevanato GroupN/A€21.99-2.8%N/A+3.4%€6.66B€1.19B40.725,521Positive NewsIRTCiRhythm Technologies1.5995 of 5 stars$165.68-2.0%$162.64-1.8%+141.4%$5.43B$591.84M-56.552,000GKOSGlaukos4.782 of 5 stars$91.78-2.5%$127.42+38.8%-29.8%$5.40B$383.48M-55.62780Positive NewsTMDXTransMedics Group3.1855 of 5 stars$114.97-4.1%$123.00+7.0%-33.6%$4.09B$441.54M62.10210Positive NewsGap DownSLNOSoleno Therapeutics4.5621 of 5 stars$66.51-3.0%$115.09+73.0%+37.3%$3.64BN/A-16.0730Positive NewsNVSTEnvista3.7916 of 5 stars$21.15-2.6%$20.92-1.1%+13.3%$3.61B$2.51B25.2612,300News CoveragePositive NewsLIVNLivaNova1.7309 of 5 stars$56.35+0.8%$59.71+6.0%+13.0%$3.05B$1.25B-14.492,900News CoveragePositive News Related Companies and Tools Related Companies Smith & Nephew SNATS Competitors Solventum Competitors Penumbra Competitors Stevanato Group Competitors iRhythm Technologies Competitors Glaukos Competitors TransMedics Group Competitors Soleno Therapeutics Competitors Envista Competitors LivaNova Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BLCO) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Bausch + Lomb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
